[The Phase III clinical study of Hengrui ADC's innovative drug Ruikang trastuzumab alone or in combination with pertuzumab as first-line treatment of HER2-positive advanced breast cancer has reached the primary endpoint] August 31, according to Hengrui Medicine news, recently, Suzhou Shengdia Biopharmaceutical Co., Ltd., a subsidiary of Hengrui Pharmaceuticals, independently developed a HER2-targeting drug Preliminary interim analysis of the pivotal Phase III clinical study of the antibody drug conjugate SHR-A1811 for the first-line treatment of HER2-positive recurrent or metastatic breast cancer showed that both trial groups achieved the primary endpoint of PFS, showing a statistically significant and clinically meaningful improvement compared with standard treatment. The results of this study show that Ruikang trastuzumab with or without pertuzumab compared with docetaxel combined with trastuzumab and pertuzumab (THP regimen) can significantly extend the progression-free survival (PFS) of first-line patients. The company will submit a pre-market communication application to the Drug Evaluation Center of the State Drug Administration in the near future.